p= 0.03), use of 3rd generation SU ; p= 0.002), and chronic renal disease ; p= 0.01). ConClusions: In conclusion, multiple factors, including efficacy and hypoglycemia, are associated with discontinuation of SU treatment after insulin initiation. objeCtives: Sulfonylurea (SU) may be discontinued or down-titrated due to hypoglycemia. Hypoglycemia may be more concerning for patients not receiving aggressive efficacy-driven treatment such as the dual-therapy of SU and insulin. A retrospective cohort study using the MarketScan database was conducted to assess the association between hypoglycemia and therapy changes (discontinuation or down-titration) among adults receiving SU therapy without insulin. Methods: Patients with the first SU prescription (Rx) (index date) in 2009-2011, ≥ 18 years of age on the index date, and with ≥ 1 year continuous enrollment pre-and postindex were included. Patients were excluded if they received insulin within the 1-year pre-or post-index, had ≥ 2 SUs on the index date, or had type 1, gestational or secondary diabetes. Therapy changes were determined during the 1-year postindex period. Discontinuation occurred when consecutive SU fills were ≥ 90 days apart. Down-titration occurred when an SU fill had a lower equivalent dose than the index dose. Hypoglycemic events were identified using ICD-9 code between the index date and the therapy change or the end of the 1-year post-index period. Cox regression was used to evaluate the association between hypoglycemic events and therapy changes. Results: 97,570 patients were included in the study, of which 50,854 (52.1%) experienced therapy changes within 1-year post-index. Patients with hypoglycemic events were at significantly higher risk for therapy changes (HR= Guideline (CPG) 2009 in the management of diabetes mellitus with co-morbidities in Malaysia. Methods: Cross-sectional study was done at a tertiary-care hospital in Malaysia. Total 51 physicians and 1020 patients' prescriptions written by same physicians (20 prescriptions per physician) were analyzed. All patients had diabetes mellitus with co-morbidities. Depending on the recommendations of CPG 2009, the prescriptions were clustered as adherent and non-adherent prescriptions. All obtained data were analyzed using descriptive and inferential statistics. Results: A statistically significant negative association (Ф= 0.094, p-value= 0.003) was observed between diabetes mellitus control and co-morbidities. CPG adherent had statistically weak negative association (Ф= -0.081, p-value= 0.010) with patients having co-morbidities (41.6%). No statistically significant association was observed between CPG adherence and any other co-morbidity. Majority of the patients received guidelines-compliant pharmacotherapy. The overall good level of physician adherence with CPG 2009 was observed in the management of diabetes mellitus with comorbidities. ConClusions: The study explored several features of prescription pattern of the physicians involved in the management of diabetes mellitus with co-morbidities and recognized the need for improvement in their prescription pattern for treating the diabetes mellitus. objeCtives: Diabetes is associated with a number of microvascular and macrovascular complications. Diabetic macular edema (DME) is one of these complications and is among the leading causes of vision impairment. However, little data exists as to the patient-related burden of DME in Europe and the aim of the current study was to address this gap. Methods: Data from the 2013 5EU (France, Germany, Italy, Spain, and UK) National Health and Wellness Survey (NHWS) were used (N= 62,000). The NHWS is a patient-reported survey administered to a demographically representative sample of adults (with respect to age, sex, and region). Patients who reported experiencing DME were compared with a propensity-scored matched control group of patients with diabetes but without DME. Matching variables included demographics, comorbidities (Charlson comorbidity index [CCI]), and diabetes history. Post-match, patients with DME and matched controls were compared on health outcomes (SF-36v2, Work Productivity and Activity Impairment, and selfreported health care resource utilization) using general linear models. Results: 4,088 patients reported diabetes (6.6%). Of these, 296 (7.2%) reported having DME. Patients with DME were more likely to have type 1 diabetes (26.4% vs. 8.5%), had been diagnosed with diabetes for longer (54.4% vs. 20.7% were diagnosed 16+ years), were more likely to use insulin (68.6% vs. 27.3%), and had a greater comorbidity burden (CCI = 2.2 vs. 1.6) (all p< .05), among other differences. After matching on these variables, patients with DME (n= 286) reported significantly worse physical health status (PCS: 41.1 vs. 43.2), greater overall work impairment (36.2% vs. 25.64%), and objeCtives: HIPOS-ER is the first national Hypoglycemia study in Portugal collecting specific resource data directly in the hospitals. Here we aim to describe the average cost of severe hypoglycemic event by anti-hyperglycemic agent (AHA) class. Methods: The study was conducted in 7 centers in mainland Portugal for a period of 12 months (Jan13-Jan14). Patient level data and resource utilization were collected. Unit costs for 2014 were extracted from official sources. Regarding emergency room (ER) attendance, costs were calculated multiplying resource use by corresponding unit costs. For hospitalization, length of stay was multiplied by daily cost obtained through hospital account record. AHA therapy classes were: Group 1 (insulin), Group 2 (secretagogue), Group 3 (oral AHA excluding secretagogue), and Group 4 (at least one insulin and one secretagogue). Results: 238 patients were enrolled and 105 (44%) were hospitalized. The distribution based on AHA therapy: 55% (131) Group 1, 32% (75) Group 2, 7% (16) Group 3 and 7% (16) Group 4. After ER episode, Group 2 patients were more often hospitalized versus Group 1 (71% vs. 29%; p< 0.001) and Group 4 (31%; p= 0.003). The global cost was 1,493€ (34€ -26,818€ ) and hospitalization was the main cost driver accounting for 85% of costs. The total cost per AHA class was: Group 1: 1,309€ ; Group 2: 1,880€ ; objeCtives: The aim of this study was to assess the burden of severe hypoglycemia (HYPO) and diabetes ketoacidosis (DKA) in terms of incidence, treatment patterns and cost in Italy. Methods: Eligible patients were identified through a data warehouse (DENALI), which matches with a probabilistic linkage demographic, clinical and economic data of about 9.9 million individuals of Lombardy region. The study population was made of all individuals with a diagnosis of type-1 diabetes (T1DM) who, during the period 1-1-2000 to 31-12-2010 developed a first episode of severe HYPO (ICD-9-CM: 251.0-251.2) or DKA (ICD-9-CM: 250.10-250.13) leading to hospitalization (index event). The identified individuals were followed-up from the index event to a maximum of 10 years. We evaluated demographic characteristics of the study population and costs (hospitalizations, drugs and outpatient examinations/visits) from the National Health Service's perspective. Results: During the observational period 1,321 T1DM subjects had at least one hospital admission for HYPO (27.5%) or DKA (72.5%) event. Median age (min-max) at the first HYPO or DKA event was 66.9 (1.3-96.7) and 39.4 (1.0-95.7) years, respectively. The overall mortality was 14.3 deaths/100 patient-years among HYPO subjects and 7.0 among DKA ones: the difference in mortality rates between groups disappeared once controlling for age. The mean costs with 95% C.I. (€ /patient-year) for HYPO and DKA patients were, respectively 10,442 (8,755-12,129) and 9,720 (8,659-10,782) in the event year, 10,296 (8,446-12,145) and 5,805 (4,539-7,071) in the year before the event, and 5,619 (3,841-7,398) and 4,974 (3,912-6,035) in the year after the event.
objeCtives: To evaluate doctors' adherence to Malaysian Clinical Practice Guideline (CPG) 2009 in the management of diabetes mellitus with co-morbidities in Malaysia. Methods: Cross-sectional study was done at a tertiary-care hospital in Malaysia. Total 51 physicians and 1020 patients' prescriptions written by same physicians (20 prescriptions per physician) were analyzed. All patients had diabetes mellitus with co-morbidities. Depending on the recommendations of CPG 2009, the prescriptions were clustered as adherent and non-adherent prescriptions. All obtained data were analyzed using descriptive and inferential statistics. Results: A statistically significant negative association (Ф= 0.094, p-value= 0.003) was observed between diabetes mellitus control and co-morbidities. CPG adherent had statistically weak negative association (Ф= -0.081, p-value= 0.010) with patients having co-morbidities (41.6%). No statistically significant association was observed between CPG adherence and any other co-morbidity. Majority of the patients received guidelines-compliant pharmacotherapy. The overall good level of physician adherence with CPG 2009 was observed in the management of diabetes mellitus with comorbidities. ConClusions: The study explored several features of prescription pattern of the physicians involved in the management of diabetes mellitus with co-morbidities and recognized the need for improvement in their prescription pattern for treating the diabetes mellitus. objeCtives: Diabetes is associated with a number of microvascular and macrovascular complications. Diabetic macular edema (DME) is one of these complications and is among the leading causes of vision impairment. However, little data exists as to the patient-related burden of DME in Europe and the aim of the current study was to address this gap. Methods: Data from the 2013 5EU (France, Germany, Italy, Spain, and UK) National Health and Wellness Survey (NHWS) were used (N= 62,000). The NHWS is a patient-reported survey administered to a demographically representative sample of adults (with respect to age, sex, and region). Patients who reported experiencing DME were compared with a propensity-scored matched control group of patients with diabetes but without DME. Matching variables included demographics, comorbidities (Charlson comorbidity index [CCI]), and diabetes history. Post-match, patients with DME and matched controls were compared on health outcomes (SF-36v2, Work Productivity and Activity Impairment, and selfreported health care resource utilization) using general linear models. Results: 4,088 patients reported diabetes (6.6%). Of these, 296 (7.2%) reported having DME. Patients with DME were more likely to have type 1 diabetes (26.4% vs. 8.5%), had been diagnosed with diabetes for longer (54.4% vs. 20.7% were diagnosed 16+ years), were more likely to use insulin (68.6% vs. 27.3%), and had a greater comorbidity burden (CCI = 2.2 vs. 1.6) (all p< .05), among other differences. After matching on these variables, patients with DME (n= 286) reported significantly worse physical health status (PCS: 41.1 vs. 43.2), greater overall work impairment (36.2% vs. 25.64%), and objeCtives: HIPOS-ER is the first national Hypoglycemia study in Portugal collecting specific resource data directly in the hospitals. Here we aim to describe the average cost of severe hypoglycemic event by anti-hyperglycemic agent (AHA) class. Methods: The study was conducted in 7 centers in mainland Portugal for a period of 12 months (Jan13-Jan14). Patient level data and resource utilization were collected. Unit costs for 2014 were extracted from official sources. Regarding emergency room (ER) attendance, costs were calculated multiplying resource use by corresponding unit costs. For hospitalization, length of stay was multiplied by daily cost obtained through hospital account record. AHA therapy classes were: Group 1 (insulin), Group 2 (secretagogue), Group 3 (oral AHA excluding secretagogue), and Group 4 (at least one insulin and one secretagogue). Results: 238 patients were enrolled and 105 (44%) were hospitalized. The distribution based on AHA therapy: 55% (131) Group 1, 32% (75) Group 2, 7% (16) Group 3 and 7% (16) Group 4. After ER episode, Group 2 patients were more often hospitalized versus Group 1 (71% vs. 29%; p< 0.001) and Group 4 (31%; p= 0.003). The global cost was 1,493€ (34€ -26,818€ ) and hospitalization was the main cost driver accounting for 85% of costs. The total cost per AHA class was: Group 1: 1,309€ ; Group 2: 1,880€ ; Group 3: 1,350€ ; Group 4: 1,330€ . When comparing ER-only vs. hospitalized: Group 1: 167€ vs. 4,105€ ; Group 2: 185€ vs. 2,583€ ; Group 3: 156€ vs. 2,278€ ; Group 4: 237€ vs. 3,734€ . Group 1 accounted for 48% of overall costs, Group 2 40%, Groups 3 and 4, 6% each. Group 2 had the highest hospitalization rate (70.7%). ConClusions: AHA classes may contribute differently for costs associated with severe hypoglycemia. Insulin based therapy had the greatest overall cost followed closely by secretagogue type drugs, which were associated with more hospitalizations. Monza, Italy, 2 Charta Foundation, Milan, Italy, 3 Federico II University of Naples, Naples, Italy objeCtives: The aim of this study was to assess the burden of severe hypoglycemia (HYPO) and diabetes ketoacidosis (DKA) in terms of incidence, treatment patterns and cost in Italy. Methods: Eligible patients were identified through a data warehouse (DENALI), which matches with a probabilistic linkage demographic, clinical and economic data of about 9.9 million individuals of Lombardy region. The study population was made of all individuals with a diagnosis of type-1 diabetes (T1DM) who, during the period 1-1-2000 to 31-12-2010 developed a first episode of severe HYPO (ICD-9-CM: 251.0-251.2) or DKA (ICD-9-CM: 250.10-250.13) leading to hospitalization (index event). The identified individuals were followed-up from the index event to a maximum of 10 years. We evaluated demographic characteristics of the study population and costs (hospitalizations, drugs and outpatient examinations/visits) from the National Health Service's perspective. Results: During the observational period 1,321 T1DM subjects had at least one hospital admission for HYPO (27.5%) or DKA (72.5%) event. Median age (min-max) at the first HYPO or DKA event was 66.9 (1.3-96.7) and 39.4 (1.0-95.7) years, respectively. The overall mortality was 14.3 deaths/100 patient-years among HYPO subjects and 7.0 among DKA ones: the difference in mortality rates between groups disappeared once controlling for age. The mean costs with 95% C.I. (€ /patient-year) for HYPO and DKA patients were, respectively 10,442 (8,755-12,129) and 9,720 (8,659-10,782) in the event year, 10,296 (8,446-12,145) and 5,805 (4,539-7,071) in the year before the event, and 5,619 (3,841-7,398) and 4,974 (3,912-6,035) in the year after the event. Hospitalizations represented the driver of total costs: in the year of event and in the year after it varied from 70 to 56% and 76 to 60% for HYPO and DKA patients, respectively. ConClusions: This study attempted to address the burden of severe T1DM HYPO and DKA events in Italy in an unselected population. The burden showed to be relevant in terms of incidence, mortality and costs. 
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